Navigation Links
Cambrex Manufacturing Facility Completes Successful US FDA Inspection
Date:12/16/2013

EAST RUTHERFORD, N.J., Dec. 16, 2013 /PRNewswire/ -- Cambrex Corporation (NYSE: CBM, "Cambrex") announced that the US Food and Drug Administration (FDA) completed an inspection of Cambrex's active pharmaceutical ingredient (API) manufacturing facility in Charles City, Iowa. The inspection found the site to be compliant with the principles and guidelines of Good Manufacturing Practice (GMP) and no Form 483 observations were issued. The US FDA authorities inspected the facility from July 31 to August 2, 2013.

Joe Nettleton, Vice President Operations and Charles City Site Director commented, "We are very pleased with the results of this latest FDA inspection, which further strengthens our track record of outstanding regulatory compliance. We commit significant resources and work diligently to maintain high quality standards and continuously improve quality platforms within Cambrex."

The entire facility and the quality systems used for the manufacture and release of APIs and food grade products were subject to a detailed compliance inspection. This follows successful inspections at Charles City made previously by the US FDA in March 2010 and February 2012, neither of which resulted in any issued 483 observations, the Korean FDA in January 2012 and the Medicines and Healthcare Products Regulatory Agency (MHRA) of the UK October 2011, after which a GMP certificate for a drug product intermediate was issued.     

About Cambrex
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics.  We offer APIs, advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Our development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage form products. For more information, please visit http://www.cambrex.com


'/>"/>
SOURCE Cambrex Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Cambrex to Present at Oppenheimer 24th Annual Healthcare Conference
2. Cambrex To Present At UBS Global Healthcare Conference
3. Cambrex Reschedules Third Quarter 2012 Financial Results and Earnings Call Date to November 5, 2012
4. Cambrex Reports Second Quarter 2012 Results
5. Cambrex to Announce Fourth Quarter 2011 Financial Results on February 6, 2012
6. InstantGMP Completes Updates to v2.03 of their Manufacturing Execution System with Electronic Batch Records
7. New In-Depth Report on Demand and Supply for Contract Manufacturing of Injectable Drugs Through 2019
8. Genesis Herb Company Selects InstantGMP as their Manufacturing Execution System with Electronic Batch Records
9. Pfenex Inc. Awards Paragon Bioservices a Contract for cGMP Manufacturing of its Recombinant Protective Antigen (rPA), for Phase 1 Clinical Trial of its Anthrax Vaccine
10. ACell Expands Indiana Manufacturing Facility to Support Growth
11. Samsung BioLogics Signs a Strategic Manufacturing Partnership with Roche
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/17/2017)... ... July 17, 2017 , ... The Academy of Model Aeronautics (AMA) ... Model Aviation Day will take place from 9 a.m. to 2 p.m. at the ... for all ages. , Aviation Adventure Day will be packed with entertaining activities for ...
(Date:7/17/2017)... (PRWEB) , ... July 17, 2017 , ... ... are characterized by a wide range of overlapping clinical features. The advancement of ... in the field of NDD research and testing. , However, designing a ...
(Date:7/17/2017)... , ... July 17, 2017 , ... ... its long-standing innovation strategy. A website (openinnovation.pioneer.com) dedicated to connecting third-party ... areas – trait discovery, plant breeding, enabling technologies, biologicals and digital solutions. , ...
(Date:7/15/2017)... ... July 15, 2017 , ... Cuvette manufacturer ... During this time, the people at FFS have learned that their biggest asset ... at FFS are able to launch new products to meet the changing needs of ...
Breaking Biology Technology:
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
(Date:3/30/2017)... 2017 The research team of The Hong ... fingerprint identification by adopting ground breaking 3D fingerprint minutiae recovery and ... speed and accuracy for use in identification, crime investigation, immigration control, ... ... A research team led ...
(Date:3/29/2017)... -- higi, the health IT company that operates the largest ... , today announced a Series B investment from BlueCross ... new investment and acquisition accelerates higi,s strategy to create ... health activities through the collection and workflow integration of ... and secures data today on behalf of over 36 ...
Breaking Biology News(10 mins):